ClinicalTrials.gg
TerminatedNCT02265900Updated Mar 17, 2021

Parkinson's Disease Exercise TMS PET Study

An interventional study of Exercise and Exercise in Parkinson Disease, sponsored by Pacific Parkinson's Research Centre. Terminated at 1 site in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by Pacific Parkinson's Research Centre · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Covid Restrictions have impacted longitudinal assessments for the effect of the intervention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Enrollment
155th of 212
26 · median 60
Started
2014
with 11 others
No phase
95 of 253
24 open now
Registered
85th of 253
by date
Lead sponsor
7 of 253
Pacific Parkinson's Research Centre

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 155th largest by enrollment of the 212 interventional ones that give a count, is one of 12 that started in 2014, is one of 95 with no phase, and was the 85th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

The therapeutic effects of exercise in Parkinson's disease (PD) are commonly reported, however the mechanisms are unknown. The purpose of this study is to investigate the potential mechanisms of exercise in the brain for the treatment of PD.

Read the detailed description

Positron Emission Tomography will be used to measure dopamine neuron density, endogenous dopamine release and neuroimflammation. We will also use functional magnetic resonance imaging (fMRI) to measure brain activity. Assessments will be conducted before and after a 12-week exercise intervention and 3-year follow-up. Participants will be randomly allocated into either an aerobic or a stretching intervention. Clinical measures of motor function, cognition and mood will also be assessed.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Positron Emission Tomography
  • Dopamine
  • Parkinson's Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Diagnosed with Parkinson's Disease, Exercise less than 3x per week.

Exclusion Criteria. Describe which potential participants will be excluded from participation, and list the criteria for their exclusion.

  1. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);
  2. significant osteoporosis or arthritis;
  3. other neurological disease/complications (e.g. myopathy, stroke, brain lesion, MS);
  4. self-reports claustrophobia;
  5. history of cancer within 5 years of study participation;
  6. high dose of radiation from other procedures within the year;
  7. not able to tolerate being off PD medication for up to 24 hours;
  8. a female subject who is breast-feeding or pregnant.
  9. Subjects who regularly use anti-inflammatories (only excluded for PBR scans).

Exclusion criteria for MRI scanning and magnetic stimulation from repetitive Transcranial Magnetic Stimulation (rTMS) scanning includes:

  1. artificial heart valve;
  2. brain aneurysm clip;
  3. electrical stimulator for nerves or bones;
  4. ear or eye implant;
  5. implanted drug infusion pump;
  6. coil, catheter, or filter in any blood vessel;
  7. orthopedic hardware (artificial joint, plate, screws);
  8. other metallic prostheses;
  9. shrapnel, bullets, or other metal fragments;
  10. surgery or tattoos (including tattooed eyeliner) in the last six weeks;
  11. brain surgery
  12. have a cardiac pacemaker, wires or defibrillator;
  13. have had an injury where a piece of metal lodged in the eye or orbit;
  14. have a ferromagnetic aneurysm clip; and
  15. have a history of seizures/epilepsy
  16. history of severe or uncontrolled headaches/migraines
  17. taking medications that lower seizure threshold (e.g. amitryptiline, haloperidol)

Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:

  1. significant cognitive impairment or depression;
  2. significant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or
  3. failure to comply with the exercise or stretching intervention program by not completing at least 30 of the 36 exercise classes.
  4. Severe/multiple head trauma(s)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Exercise 1

    One type of exercise

    Other: Exercise

  • Placebo comparator
    Exercise 2

    A different type of exercise

    Other: Exercise

Interventions

  • OtherExercise

    One type of exercise

  • OtherExercise

    A different type of exercise

06

What researchers measure

Primary outcomes

  1. Change in Dopamine release measured by RAC PET

    Time frame: 4 months

07

Study locations

1 site
  • Pacific Parkinson's Research Centre
    Vancouver, British Columbia V6T 2B5, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of Mar 2020 and a completion of Mar 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2014
First posted
Oct 16, 2014
Start
Nov 2014
Primary completionActual
Mar 12, 2020
CompletionActual
Mar 12, 2020
Last update
Mar 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02265900
Lead sponsor
Pacific Parkinson's Research Centre
Responsible party
A. Jon Stoessl (Director of Clinical PET, Pacific Parkinson's Research Centre) — Principal investigator
First posted
Oct 16, 2014
Start date
Nov 2014
Primary completion
Mar 12, 2020
Completion
Mar 12, 2020
Last update
Mar 17, 2021

Study contacts

A.J. Stoessl, MD
principal investigator · Pacific Parkinson's Research Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion